{"id":8756,"date":"2021-10-12T08:31:31","date_gmt":"2021-10-12T08:31:31","guid":{"rendered":"http:\/\/cvx.vc\/?p=8756"},"modified":"2021-10-12T08:31:31","modified_gmt":"2021-10-12T08:31:31","slug":"lifescience-fond-investerer-i-ny-biotech-komet","status":"publish","type":"post","link":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/","title":{"rendered":"LifeScience-fond investerer i ny BioTech-komet"},"content":{"rendered":"<p>Den nordiske LifeScience-fond Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Lupus er en sygdom, som angriber fejlagtigt raske kropsceller og v\u00e6v, uden at der eksisterer antigener. Den nylige kapitaludvidelse fra Eir Ventures skal bruges p\u00e5 forberedelserne til kliniske fasefors\u00f8g for at f\u00e5 produktet godkendt til kommerciel brug.<\/p>\n<p>&#8220;<em>Vi skal rejse en endnu st\u00f8rre runde i 2022 eller 2023, som skal bringe os til &#8216;proof-of-concept&#8217; i klinikken. Det n\u00f8jagtige bel\u00f8b kender vi ikke endnu, men det bliver et trecifret millionbel\u00f8b i danske kr. vi skal ud at hente,<\/em>&#8221; udtaler Ingelise Saunders, CEO og bestyrelsesformand hos ISD Immunotec, til MedWatch.<\/p>\n<p>V\u00e6kstvirksomheden blev stiftet i 2007 og ejes i dag bl.a. af Novo Holdings, der forvalter over 450 mia. kr. Ingen af de to parter \u00f8nsker at oplyse, hvor meget Eir Ventures konkret har investeret i v\u00e6kstkometen ISD Immunotec.<\/p>\n<p>L\u00e6s hele artiklen p\u00e5 KapWatch <a href=\"https:\/\/kapwatch.dk\/nyheder\/venturefonde\/article13359062.ece\"><em><strong>her<\/strong><\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.<\/p>\n","protected":false},"author":25,"featured_media":8758,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.4 (Yoast SEO v23.5) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LifeScience-fond investerer i ny BioTech-komet | CVX Ventures<\/title>\n<meta name=\"description\" content=\"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\" \/>\n<meta property=\"og:locale\" content=\"da_DK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LifeScience-fond investerer i ny BioTech-komet\" \/>\n<meta property=\"og:description\" content=\"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\" \/>\n<meta property=\"og:site_name\" content=\"CVX Ventures\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cvxventures\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-12T08:31:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Jessica Axholt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet af\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Jessica Axholt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimeret l\u00e6setid\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\"},\"author\":{\"name\":\"Kim Jessica Axholt\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\"},\"headline\":\"LifeScience-fond investerer i ny BioTech-komet\",\"datePublished\":\"2021-10-12T08:31:31+00:00\",\"dateModified\":\"2021-10-12T08:31:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg\",\"articleSection\":[\"Blogindl\u00e6g\"],\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\",\"url\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\",\"name\":\"LifeScience-fond investerer i ny BioTech-komet | CVX Ventures\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg\",\"datePublished\":\"2021-10-12T08:31:31+00:00\",\"dateModified\":\"2021-10-12T08:31:31+00:00\",\"description\":\"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#breadcrumb\"},\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg\",\"width\":960,\"height\":540},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/cvx.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LifeScience-fond investerer i ny BioTech-komet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvx.vc\/da\/#website\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"name\":\"CVX Ventures\",\"description\":\"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder\",\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvx.vc\/da\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"da-DK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cvx.vc\/da\/#organization\",\"name\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"width\":827,\"height\":394,\"caption\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/cvxventures\/\",\"https:\/\/www.linkedin.com\/company\/cvxventures\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\",\"name\":\"Kim Jessica Axholt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"caption\":\"Kim Jessica Axholt\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LifeScience-fond investerer i ny BioTech-komet | CVX Ventures","description":"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/","og_locale":"da_DK","og_type":"article","og_title":"LifeScience-fond investerer i ny BioTech-komet","og_description":"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.","og_url":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/","og_site_name":"CVX Ventures","article_publisher":"https:\/\/www.facebook.com\/cvxventures\/","article_published_time":"2021-10-12T08:31:31+00:00","og_image":[{"width":960,"height":540,"url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg","type":"image\/jpeg"}],"author":"Kim Jessica Axholt","twitter_card":"summary_large_image","twitter_misc":{"Skrevet af":"Kim Jessica Axholt","Estimeret l\u00e6setid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#article","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/"},"author":{"name":"Kim Jessica Axholt","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb"},"headline":"LifeScience-fond investerer i ny BioTech-komet","datePublished":"2021-10-12T08:31:31+00:00","dateModified":"2021-10-12T08:31:31+00:00","mainEntityOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg","articleSection":["Blogindl\u00e6g"],"inLanguage":"da-DK","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/","url":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/","name":"LifeScience-fond investerer i ny BioTech-komet | CVX Ventures","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg","datePublished":"2021-10-12T08:31:31+00:00","dateModified":"2021-10-12T08:31:31+00:00","description":"Eir Ventures skyder penge efter BioTech-virksomheden ISD Immunotec, der udvikler p\u00e5 et l\u00e6gemiddel, som kan behandle en variant af den autoimmune sygdom Lupus. Nu skal kapitaludvidelsen bruges p\u00e5 at f\u00e5 produktet godkendt.","breadcrumb":{"@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#breadcrumb"},"inLanguage":"da-DK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/"]}]},{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#primaryimage","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Ingelise.jpg","width":960,"height":540},{"@type":"BreadcrumbList","@id":"https:\/\/cvx.vc\/da\/insights\/lifescience-fond-investerer-i-ny-biotech-komet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/cvx.vc\/"},{"@type":"ListItem","position":2,"name":"LifeScience-fond investerer i ny BioTech-komet"}]},{"@type":"WebSite","@id":"https:\/\/cvx.vc\/da\/#website","url":"https:\/\/cvx.vc\/da\/","name":"CVX Ventures","description":"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder","publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvx.vc\/da\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"da-DK"},{"@type":"Organization","@id":"https:\/\/cvx.vc\/da\/#organization","name":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor","url":"https:\/\/cvx.vc\/da\/","logo":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","width":827,"height":394,"caption":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor"},"image":{"@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cvxventures\/","https:\/\/www.linkedin.com\/company\/cvxventures\/"]},{"@type":"Person","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb","name":"Kim Jessica Axholt","image":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","caption":"Kim Jessica Axholt"}}]}},"_links":{"self":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/8756"}],"collection":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/comments?post=8756"}],"version-history":[{"count":0,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/8756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media\/8758"}],"wp:attachment":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media?parent=8756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/categories?post=8756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/tags?post=8756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}